Current Scientific Rationale for the Use of Somatostatin Analogs and mTOR Inhibitors in Neuroendocrine Tumor TherapyCorinne Bousquet, Stéphane Pyronnet, Mounira Chalabi et al.|The Journal of Clinical Endocrinology & Metabolism|2011Cited by 87